Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Ovid Therapeutics (OVID) Accumulated Depreciation & Amortization (2020 - 2025)

Ovid Therapeutics' Accumulated Depreciation & Amortization history spans 6 years, with the latest figure at $273000.0 for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization fell 55.46% year-over-year to $273000.0; the TTM value through Dec 2025 reached $273000.0, down 55.46%, while the annual FY2025 figure was $273000.0, 55.46% down from the prior year.
  • Accumulated Depreciation & Amortization reached $273000.0 in Q4 2025 per OVID's latest filing, up from $256000.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $613000.0 in Q4 2024 to a low of $73807.0 in Q1 2022.
  • Average Accumulated Depreciation & Amortization over 5 years is $282704.0, with a median of $248000.0 recorded in 2025.
  • The largest YoY upside for Accumulated Depreciation & Amortization was 116.17% in 2022 against a maximum downside of 63.82% in 2022.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $237079.0 in 2021, then skyrocketed by 116.17% to $512505.0 in 2022, then grew by 10.83% to $568000.0 in 2023, then increased by 7.92% to $613000.0 in 2024, then plummeted by 55.46% to $273000.0 in 2025.
  • Per Business Quant, the three most recent readings for OVID's Accumulated Depreciation & Amortization are $273000.0 (Q4 2025), $256000.0 (Q3 2025), and $240000.0 (Q2 2025).